Skip to main content
Fig. 1 | Trials

Fig. 1

From: Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial

Fig. 1

Overview of ALSUMMIT trial design. Data from study Group 1 and the control group will be analysed by JRS score at 6 months after the single-cycle treatments. Study Group 2 and the control group will be analysed by JRS score at 12 months after the combined single-cycle intrathecal therapy and three additional booster injections of MSC (Lenzumestrocel) treatment. CSF, cerebrospinal fluid; ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-revised; JRS, joint rank score

Back to article page

Trials

ISSN: 1745-6215